New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
16:27 EDTITMN, LOCK, CPB, BRCM, TXN, MU, NVDA, AZN, PFE, DTV, TOn The Fly: Closing Wrap
Stocks on Wall Street were higher following a trading day marked by light volume, a quiet economic calendar and two headline making M&A announcements. The averages began the day slightly below the flat line, but within minutes the Nasdaq and S&P 500 made it into positive ground. The Dow followed by the end of the morning, but the averages moved in a narrow range from there. Despite the range-bound trading, the market internals pointed to a pretty broad based move higher, with advancers ahead of declining stocks by almost 2 to 1. ECONOMIC EVENTS: In the U.S., no major domestic economic data was reported. COMPANY NEWS: AT&T (T) shares slid 36c, or 0.98%, to $36.38 after the company confirmed over the weekend that it has agreed to acquire DirecTV (DTV) for $95.00 per share, including $28.50 per share in cash and $66.50 per share in AT&T stock. After the announcement, analysts at Raymond James upgraded AT&T to Buy from Market Perform, noting that they do not expect another buyer to emerge for DirecTV. Meanwhile, DirecTV shares were downgraded to Equal Weight from Overweight at Evercore and to Hold from Buy at Wunderlich. Shares of DirecTV fell $1.53, or 1.77%, to $84.65 after the deal, which has been widely speculated about in the media in recent weeks, was confirmed... Also over the weekend, Pfizer (PFE) raised its bid for AstraZeneca (AZN), but the U.K. drugmaker again rejected this "final" takeover proposal. Shares of Pfizer rose 16c, or 0.55%, to $29.28 after the rejection, while shares of AstraZeneca trading in New York dropped $9.64, or 12.01%, to $70.64. MAJOR MOVERS: Among the notable gainers was InterMune (ITMN), which gained $4.61, or 13.44%, to $38.92 after reporting results from a study evaluating pirfenidone and having its shares upgraded to Outperform at Leerink. Also higher was NVIDIA (NVDA), which rose 58c, or 3.23%, to $18.54 after it was one of several semiconductor stock, along with Micron (MU), Texas Instruments (TXN), and Broadcom (BRCM), that were upgraded to Outperform from Sector Perform by RBC Capital in a note to investors earlier today. Among the noteworthy losers was LifeLock (LOCK), which fell $2.28, or 17.57%, to $10.70 after disclosing that the company is going to temporarily suspend its Wallet mobile application since it is not fully compliant with applicable payment card industry security standards. Also lower were shares of Campbell Soup (CPB), which dropped $1.06, or 2.35%, to $44.06 after the company reported mixed third quarter results and lowered its fiscal 2014 outlook. INDEXES: The Dow was up 20.55, or 0.12%, to 16,511.86, the Nasdaq was up 35.23, or 0.86%, to 4,125.81, and the S&P 500 was up 7.22, or 0.38%, to 1,885.08.
News For T;DTV;PFE;AZN;NVDA;MU;TXN;BRCM;CPB;LOCK;ITMN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 20, 2014
14:29 EDTTXNEarnings Preview: Texas Instruments down 9% over last three months
Semiconductor maker Texas Instruments (TXN) is expected to report third quarter earnings after the close on Monday, October 20, with a conference call scheduled for 5:30 pm ET. EXPECTATIONS: Analysts are looking for earnings per share of 71c on revenue of $3.46B. The consensus range is 66c-74c for EPS on revenue of $3.44B-$3.5B, according to First Call. Along with its last earnings report, Texas Instruments guided to Q3 EPS of 66c-76c on revenue of $3.31B-$3.59B. LAST QUARTER: On July 21, Texas Instruments reported second quarter EPS of 62c, which was higher than analysts' consensus of 59c. The company's revenue of $3.29B exceeded analysts' expectation of $3.27B. Texas Instruments noted that the restructuring changes which occurred in Q2 are positioned to be nil in Q3 and noted that it anticipated utilization in Q3 to remain consistent with Q2 levels. NEWS: On September 18, Texas Instruments increased its quarterly dividend by 13% to 34c. WHAT'S NOTABLE: After the close on October 9, Microchip (MCHP), which develops microcontroller and analog semiconductors, said that it had experienced a number of negative trends during the quarter, including a weaker than usual September, weakness in China, and significant inventory builds at its distributor customers. Microchip President and CEO Steve Sanghi claimed his company often sees the turn of the semiconductor industry ahead of others, noting that it reports sales from distribution on a sell-through basis and that it does business with over 80,000 customers. Sanghi stated, "We believe that another industry correction has begun and that this correction will be seen more broadly across the industry in the near future." STREET RESEARCH: Analysts were fairly quiet on Texas Instruments during the quarter. The day after the company issued its Q2 earnings report, Sterne Agee believed that Texas Instruments' commentary on 4G telecom, auto and industrial strength should be positive for Spansion (CODE). RBC Capital noted on the same day that Texas Instruments had "strong" Q2 results, particularly in its execution, while its operating margin leverage was "impressive. The firm maintained a $57 price target and Outperform rating on the stock. On July 24, Tigress Financial upgraded Texas Instruments to Neutral from Underperform. PRICE ACTION: Over the last three months, Texas Instruments' shares are down about 9%. Since October 10, the day after Microchip's warning on the industry correction it believes has begun, Texas Instruments shares are down over 3%. In afternoon trading before tonight's report, Texas Instruments was up 1.7% to $44.41.
12:36 EDTMUOptions with decreasing implied volatility
Subscribe for More Information
12:10 EDTTXNTexas Instruments technical notes ahead of earnings
Subscribe for More Information
08:45 EDTTXNTexas Instruments volatility elevated into Q3 and outlook
Subscribe for More Information
07:47 EDTAZN, PFEPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:19 EDTAZNIBC Life Sciences to hold a conference
Subscribe for More Information
07:15 EDTTAT&T weekly volatility elevated into Q3 and outlook
Subscribe for More Information
07:15 EDTPFEAmerican Academy of Child & Adolescent Psychiatry to hold annual meeting
Subscribe for More Information
07:14 EDTAZNEuropean College of Neuropsychopharmacology to hold a conference
27th ECNP Congress is being held in Berlin, Germany on October 18-21.
07:12 EDTPFECongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:11 EDTPFEAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTPFEAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
06:53 EDTMUMicron upgraded to Outperform from Sector Perform at Pacific Crest
Subscribe for More Information
05:58 EDTMUMicron upgraded to Outperform from Sector Perform at Pacific Crest
October 17, 2014
16:41 EDTPFEPfizer confirms FDA labeling approval for EMBEDA capsules
Pfizer announced that the FDA has approved an updated label for EMBEDA extended-release capsules, for oral use to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal routes when crushed. However, abuse of EMBEDA by these routes is still possible. The updated label also includes data from a human abuse potential study of intravenous, or IV, morphine and naltrexone to simulate crushed EMBEDA. However, it is unknown whether the results with simulated crushed EMBEDA predict a reduction in abuse by the IV route until additional postmarketing data are available. EMBEDA is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Pfizer expects EMBEDA will be available in the U.S. in early 2015.
16:30 EDTPFEFDA approves new labeling from Embeda extended-release capsules
Subscribe for More Information
11:51 EDTMUStocks with call strike movement; MU DAL
Subscribe for More Information
10:51 EDTDTVOptions with increasing implied volatility
Options with increasing implied volatility: COV DISH HLT QEP GREK BKW BYI LLY DTV TIBX
09:16 EDTMUMicron management to meet with MKM Partners
Meetings to be held in New York on October 23 and in the Mid-Atlantic area on October 24 hosted by MKM Partners.
07:31 EDTMUSamsung first to market with new multilayer NAND technology, Nikkei says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use